This year’s American Society of Hematology (ASH) meeting, which is taking place in Atlanta, came to a close earlier today.  However, yesterday, the third day of the meeting, was packed with myeloma-related presentations.

Given the number of myeloma presentations made yesterday, The Beacon will summarize the four most important of yesterday’s oral presentation sessions as well as a number of the most important poster presentations in updates such as this one.  Summaries of the first three key oral presentation sessions were published yesterday and earlier today.  This update covers presentations from the …

We continue to report the latest myeloma-related findings from this year’s American Society of Hematology (ASH) meeting, which has come to a close in Atlanta.  Yesterday was the third day of the meeting and featured the most myeloma-related presentations in a given day.

Yesterday, there were nearly 50 myeloma-related talks given during 11 oral presentation sessions.  The Beacon will therefore summarize presentations from the four most important sessions in updates such as this one.

This update covers presentations from the third of the four key oral presentation sessions. Updates published yesterday …

This year’s American Society of Hematology (ASH) meeting con­tinues in Atlanta.  Yesterday was the third day of the meeting and the busiest day in terms of myeloma-related presentations.  It was packed full of both oral and poster presentations.

There were so many myeloma-related talks given yesterday that many of them were held simultaneously.  The Beacon will therefore summarize presentations from the four most important sessions in updates such as this one.

This update covers presentations from the second of the four key oral presentation sessions.  An update published yesterday covers presentations from …

Today is the third day of the American Society of Hematology (ASH) 2012 annual meeting in Atlanta, and it is packed full with multiple myeloma-related presentations. Presentations started early in the morning and will con­tinue through the afternoon.

Over the course of today, at least 11 different oral sessions, many of which are being held simultaneously, will include presentations about myeloma-related topics.  The Beacon will summarize presentations from the four most relevant sessions in updates such as this one.  This update, in particular, covers presentations from the first of those four oral …

Yesterday was the second day of the 2012 American Society of Hematology (ASH) annual meeting.  Although the myeloma-related sessions got a bit of a late start, the day featured a wide range of interesting presentations about multiple myeloma.

Many myeloma-related oral presentations were given in the afternoon and were summarized in updates published yesterday and earlier today.

During the evening yesterday, a poster session took place where important new research findings were summarized in posters displayed throughout a large conference hall. The studies covered a variety of myeloma-related topics, ranging …

Yesterday was the sec­ond day of the 2012 American Society of He­ma­tol­ogy (ASH) annual meeting, which is being held in Atlanta.

The day's myeloma-related pre­sen­ta­tions began in the afternoon with three sessions of oral pre­sen­ta­tions.  Two of the sessions focused on re­­sults from clin­i­cal trials, most of which studied drugs that are still being devel­oped for the treat­ment of mul­ti­ple myeloma.  The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clin­i­cal trial re­­sults.

An up­date pub­lished yes­ter­day evening summarized the re­­sults for the …

This year’s American Society of Hematology (ASH) annual meeting, which is being held in Atlanta, began yesterday and goes through Tuesday.

Today’s myeloma-related presentations began this afternoon with three sessions of oral presentations.  Two of the sessions focused on results from clin­i­cal trials, most of which studied drugs that are still under devel­op­ment as poten­tial treat­ments for multiple myeloma.  The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clin­i­cal trial results.

This article will summarize the first oral session about multiple myeloma treat­ments, …